Drug intelligence / Profile preview

Protein Based Pneumococcal Vaccine

Development stage: Phase 1
Lead developer: CanSino Biologics
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Protein Based Pneumococcal Vaccine (PBPV) is a vaccine developed by CanSino Biologics Inc. to prevent infections caused by *Streptococcus pneumoniae*. These infections can lead to serious health problems, particularly in infants and the elderly. The vaccine aims to address the limitations of traditional polysaccharide-based vaccines, which often fail to cover all polysaccharide types, especially in adults, by utilizing a protein-based approach to induce an immune response.

Other names: recombinant pneumococcal protein vaccine

Targets

PspA (Pneumococcal surface protein A)Ply (Pneumolysin)

Beyond the preview

Go deeper on Protein Based Pneumococcal Vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Protein Based Pneumococcal Vaccine.

Explore the full profile